Log in

Start free trial
New Studies Question Utility of Gene Expression Testing for Cancers With Unknown Primary Site, Low-Risk Breast Cancer

New Studies Question Utility of Gene Expression Testing for Cancers With Unknown Primary Site, Low-Risk Breast Cancer

by | Feb 25, 2019 | Clinical Diagnostics Insider, Diagnostic Testing and Emerging Technologies, Top of the News-dtet

From - Diagnostic Testing & Emerging Technologies
Gene expression profiling has been making inroads into clinical cancer care, with application in cancer classification, most notably with…


. . . read more

This content is for Paid Members only.
Login Register
Study Showing PGx Testing Improves Depression Outcomes, Key to Myriad’s Reimbursement Strategy

Study Showing PGx Testing Improves Depression Outcomes, Key to Myriad’s Reimbursement Strategy

by | Feb 18, 2019 | Clinical Diagnostics Insider, Diagnostic Testing and Emerging Technologies, Emerging Tests-dtet, The Business of Testing-dtet

From - Diagnostic Testing & Emerging Technologies
Pharmacogenomic testing (PGx) provides clinically meaningful improvement in response and remission rates for difficult-to-treat depression patients over standard of care, according to…


. . . read more

This content is for Paid Members only.
Login Register